

S 146

Cap Insulin Prices Act

Congress: 118 (2023–2025, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Jan 30, 2023

Current Status: Committee on Banking, Housing, and Urban Affairs. Hearings held.

Latest Action: Committee on Banking, Housing, and Urban Affairs. Hearings held. (Jun 12, 2024)

Official Text: <https://www.congress.gov/bill/118th-congress/senate-bill/146>

Sponsor

Name: Sen. Hawley, Josh [R-MO]

Party: Republican • **State:** MO • **Chamber:** Senate

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Warnock, Raphael G. [D-GA]	D · GA		Nov 7, 2023

Committee Activity

Committee	Chamber	Activity	Date
Banking, Housing, and Urban Affairs Committee	Senate	Hearings By (full committee)	Jun 12, 2024
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Jan 30, 2023

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
118 HR 1488	Related bill	Dec 17, 2024: Referred to the Subcommittee on Health.

Summary (as of Jan 30, 2023)

Cap Insulin Prices Act

This bill reduces cost-sharing for insulin under private health insurance and the Medicare prescription drug benefit.

Specifically, the bill caps cost-sharing under private health insurance for a month's supply of selected insulin products at \$25 or 25% of a plan's negotiated price (after any price concessions), whichever is less, beginning in 2024.

The bill caps cost-sharing under the Medicare prescription drug benefit for a month's supply insulin products at \$25 beginning in 2024. The current cap on insulin products under Medicare is \$35 per month.

Actions Timeline

- **Jun 12, 2024:** Committee on Banking, Housing, and Urban Affairs. Hearings held.
- **Jan 30, 2023:** Introduced in Senate
- **Jan 30, 2023:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.